Fig. 6.

Proportion progressed at each year by ≥4 versus 0 active T2 lesions at 12 months. a Placebo/delayed treatment, ≥4 versus 0 T2 lesions at 12 months; b IFN β-1a 22 μg SC tiw, ≥4 versus 0 T2 lesions at 12 months; c IFN β-1a 44 μg SC tiw, ≥4 versus 0 T2 lesions at 12 months. No statistically significant differences were seen in any treatment group. Values were calculated with a logistic regression model with predictor (≥4 vs 0 T2 lesions) as a fixed effect; number of relapses within the previous 2 years, age, baseline EDSS score, and baseline burden of disease were independent variables, and p-values were calculated for the predictive effect of T2 lesion subgroups. EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly